Israel Englander Annexon, Inc. Transaction History

Millennium Management LLC

$175 Billion
Q1 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Annexon, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 175,303 shares of ANNX stock, worth $364,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares

175,303

Previous 155,676 12.61%

Holding current value

$364,630

Previous $798,000 57.64%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.93 - $5.5 $37,880 - $107,948	19,627 Added 12.61%	175,303 $338,000
Q4 2024 Feb 14, 2025	BUY	$4.44 - $7.63 $368,613 - $633,450	83,021 Added 114.27%	155,676 $798,000
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $1.23 Million - $1.98 Million	-274,557 Reduced 79.07%	72,655 $430,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $6.79 $4.03 Million - $6.32 Million	-930,976 Reduced 72.84%	347,212 $1.7 Million
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $1.88 Million - $3.65 Million	467,169 Added 57.6%	1,278,188 $9.16 Million
Q4 2023 Feb 14, 2024	BUY	$1.63 - $4.63 $314,893 - $894,451	193,186 Added 31.27%	811,019 $3.68 Million
Q2 2023 Aug 14, 2023	SELL	$2.1 - $6.37 $1.57 Million - $4.76 Million	-746,510 Reduced 54.72%	617,833 $2.17 Million
Q1 2023 May 15, 2023	BUY	$3.74 - $7.46 $3.13 Million - $6.25 Million	837,812 Added 159.12%	1,364,343 $5.25 Million
Q4 2022 Feb 14, 2023	SELL	$4.56 - $6.61 $99,777 - $144,633	-21,881 Reduced 3.99%	526,531 $2.72 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $526,548 - $930,938	140,413 Added 34.42%	548,412 $3.39 Million

Others Institutions Holding ANNX

# of Institutions

152

Shares Held

96.8M

Call Options Held

36.9K

Put Options Held

83K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $99M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account